Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745208 | 0.82 | ALDH1A1 (0.47) | CNR2ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL827310 | 0.82 | ALDH1A1 (0.47) | CNR2ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL827674 | 0.82 | CNR2 (0.44) | CNR2ALDH1A1LMNAHDAC3HDAC4 | |
| SCHEMBL15359201 | 0.80 | ADRA2A (0.45) | CSNK2A2CSNK2BCSNK2A1GPR35ADRA2A | |
| SCHEMBL4831587 | 0.79 | CNR2 (0.41) | CNR2ALDH1A1PTPN1LMNAHDAC3 | |
| SCHEMBL14380682 | 0.78 | CNR2 (0.41) | CNR2ALDH1A1PTPN1HDAC3HDAC4 | |
| SCHEMBL4084303 | 0.78 | PLK1 (0.54) | CNR2ALDH1A1HDAC3HDAC4HDAC1 | |
| SCHEMBL826816 | 0.78 | TSHR (0.46) | CNR2ALOX15ALDH1A1LMNATSHR | |
| SCHEMBL6337807 | 0.78 | CNR2 (0.41) | CNR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6327807 | 0.78 | GSK3B (0.44) | CNR2ALDH1A1PTPN1LMNAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111440137-B | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2022-08-16 | — | — | CN | claimed |
| CN-111440137-A | 3, 4-benzocoumarin derivative and preparation method and application thereof | 华东理工大学 | 2020-07-24 | — | — | CN | claimed |
| CN-111410603-A | Benzanthrone derivative, preparation method thereof and application thereof in functional pigment | 上海甘田光学材料有限公司 | 2020-07-14 | — | — | CN | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | NATIONAL HEALTH RES INST (TW) | 2026-02-19 | — | — | US | disclosed |
| US-20250270210-A1 | BCL-2 Inhibitor | BEIGENE, LTD. (KY) | 2025-08-28 | — | — | US | disclosed |
| US-12286430-B2 | Bcl-2 inhibitor | BEIGENE, LTD. (KY) | 2025-04-29 | — | — | US | disclosed |
| US-20240376097-A1 | BCL-2 Inhibitor | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117510483-A | Isoxazoline compounds for controlling invertebrate pests | FMC公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2006009734-A1 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-6555555-B1 | Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | disclosed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-5391567-A | Oral administeration | MACROCHEM CORPORATION (US) | 1995-02-21 | — | — | US | disclosed |
| US-5344941-A | Treatment of osteoporosis | MACROCHEM CORPORATION | 1994-09-06 | — | — | US | disclosed |
| EP-0259168-B1 | NEW WATER-SOLUBLE SALTS OF THIONAPTHENE-2-CARBOXYLIC ACID | Macrochem Corporation (US) | 1991-12-11 | — | — | EP | disclosed |
| EP-0259168-A1 | New water-soluble salts of thionapthene-2-carboxylic acid | Macrochem Corporation (US) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049060-A1 | TETRAHYDROISOQUINOLINYLMETHYLBENZAMIDE COMPOUNDS | OPRK1, OPRD1, OPRM1 | NR4A1 73/4885NR4A2 309/4885NR4A3 352/4885 |
| US-20250270210-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | NR4A1 4227/4885NR4A2 2701/4885NR4A3 3794/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | NR4A1 722/4885NR4A2 1245/4885NR4A3 652/4885 |
| US-20240376097-A1 | BCL-2 Inhibitor | BCL2, BCL2A1, BCL2L1 | NR4A1 4227/4885NR4A2 2701/4885NR4A3 3794/4885 |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | NR4A1 705/4885NR4A2 1175/4885NR4A3 1888/4885 |
| US-12286430-B2 | Bcl-2 inhibitor | BCL2, BCL2A1, BCL2L1 | NR4A1 4227/4885NR4A2 2701/4885NR4A3 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.